Molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others) that may or may not be associated with any disease.
Molecular diagnostics have been revolutionized enormously over the last few decades. It is the driving force behind the current transformation in healthcare, leading to innovations in the field of molecular biology. These innovations include next-generation sequencing, microarray technologies, liquid biopsies, early cancer detection, direct-to-consumer testing, and point-of-care assays.
The increasing incidence of infectious diseases, a rise in fatal diseases like cancer and genetic disorders, excellent prospects in the field of pharmacogenetics, increasing demand for point-of-care diagnostics and rapidly evolving technology drive the market for molecular diagnostics. The market limitations include complex regulatory framework, budget constraints, the need for high complexity testing centers, and economic turndown.
The market has been segmented by technology, products, applications, end-users and geography.
Technology: In situ hybridization (ISH and FISH), chips & microarrays, mass spectroscopy, DNA sequencing (capillary electrophoresis (CE) and next generation sequencing (NGS)), polymerase chain reaction (cold-PCR, digital-PCR, DirectLinear‰ã¢ analysis, quantitative fluorescent PCR, real-time PCR, reverse transcriptase PCR), gene chip and microfluidic microarrays, toxicogenomics, cytogenetics, nanodiagnostics, gene expression based studies, and molecular imaging (optical imaging, FDG-PET).
Currently, PCR contributes the largest share of market revenue. However, microarrays segment is expected to grow at the highest rate during the forecast period.
Products: Instruments, reagents, and software & services.
Reagents segment dominated the market with highest CAGR in 2015.
Applications: Infectious diseases, oncology, pharmacogenomics, genetic disease screening, microbiology, human leukocyte antigen typing, and blood screening.
Overall, infectious diseases segment held the dominant market share in 2015, followed by the blood screening and oncology segments.
End-users: Hospitals, academics, research laboratories and others.
Hospitals, followed by academic laboratories segment, dominated the market in 2015.
Geography: North America, Europe, APAC, Latin America and the Middle East & Africa.
The USA is currently the market leader for the global molecular diagnostics market and this trend is expected to continue. North America held a significant share of around 45% in 2015. However, developing nations of Asia-Pacific, including India and China, are projected as the fastest growing markets during the forecast period (2017 - 2022).
The key players in the diagnostic market are -
- bioMÌÄ ©rieux
Market analysis for the global molecular diagnostics market, with region-specific assessments and competition analysis on a global and regional scale.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
Identification and analysis of the macro and micro factors that affect the global molecular diagnostics market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions where this industry is growing and also identify the regions that are still untapped.
1.1 Study Deliverables
1.2 Market Definition
1.3 General Study Assumptions
1.4 Report Description
2. Research Methodology
2.2 Analysis Methodology
2.3 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. Executive Summary
4. Market Overview and Industry Trends
4.1 Current Market Scenario
4.2 Porters Five Forces Analysis
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Degree of Competition
4.2.4 Threat of Substitution
4.2.5 Threat of New Entrants
5. Drivers, Restraints, Opportunities, and Challenges (DROC Analysis)
5.1 Market Drivers
5.1.1 Large Outbreaks of Bacterial and Viral Epidemics in The World
5.1.2 Increasing Demand for Point of Care Diagnostics
5.1.4 Rapidly Evolving Technology
5.2 Market Constraints
5.2.2 Economic Turndown
5.2.3 Need for High Complexity Testing Centers
5.2.4 Limited Budgets
5.2.4 Limited Budgets
5.3 Market Opportunities
5.3.1 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
5.4 Market Challenges
5.4.1 Dearth of Trained Professionals
6. Global Molecular Diagnostics Market Segmentation
6.1 By Technology
6.1.1 In-Situ Hybridization
6.1.2 Chips and Microarrays
6.1.3 Mass Spectroscopy
6.1.4 DNA Sequencing
220.127.116.11 Capillary Electrophoresis (CE)
18.104.22.168 Next Generation Sequencing (NGS)
6.1.5 Polymerase Chain Reaction (PCR) Based Methods
22.214.171.124 DirectLinear‰ã¢ Analysis
126.96.36.199 Quantitative Fluorescent PCR
188.8.131.52 Real-Time PCR
184.108.40.206 Reverse Transcriptase PCR
6.1.7 Gene Expression Based Studies
6.1.8 Molecular Imaging
220.127.116.11 Optical Imaging
6.2 By Application
6.2.1 Infectious Disease
6.2.5 Genetic Disease Screening
6.2.6 Human Leukocyte Antigen Typing
6.2.7 Blood Screening
6.3 By Product
6.3.3 Software and Services
6.4 By End-Users
6.4.3 Research Laboratories
7. Global Molecular Diagnostics Markets: Segmentation by Geography
7.1 North America
7.2.8 Rest of Europe
7.3.5 South Korea
7.3.6 Rest of Asia-Pacific
7.4 Latin America
7.5 The Middle East & Africa
7.5.1 GCC countries
7.5.2 South Africa
8. Competitive Landscape
8.1 Mergers & Acquisitions
8.2 New Product Launches
8.3 Agreements, Collaborations & Partnerships
9. Company Profiles
9.1 Roche Diagnostics
9.2 Illumina, Inc.
9.3 Hologic Corporation
9.4 Agilent Technologies/Dako
9.6 Myriad Genetics
9.7 BD (Becton, Dickinson and Company)
9.8 Abbott Laboratories
9.9 Cepheid Inc.
9.10 Genomic Health Inc.
9.11 Grifols, S.A.
10. Future Outlook of the Market